Last reviewed · How we verify

Vabiotech — Portfolio Competitive Intelligence Brief

Vabiotech pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
PNEUMOSIL® PNEUMOSIL® phase 3 Pneumococcal conjugate vaccine Streptococcus pneumoniae capsular polysaccharides (13 serotypes) Immunology / Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Epicentre · 1 shared drug class
  2. GlaxoSmithKline · 1 shared drug class
  3. Inventprise Inc. · 1 shared drug class
  4. Korea University Guro Hospital · 1 shared drug class
  5. Merck Sharp & Dohme LLC · 1 shared drug class
  6. Papua New Guinea Institute of Medical Research · 1 shared drug class
  7. Pfizer Inc. · 1 shared drug class
  8. Sanofi · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Vabiotech:

Cite this brief

Drug Landscape (2026). Vabiotech — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/vabiotech. Accessed 2026-05-13.

Related